MHMarc De Hert

Marc De Hert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc De Hert has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 June 2016
      • Vol. 28  (2) , 139-45

    The Metabolic Syndrome Is Associated with Self-Reported Physical Complaints in Patients with Bipolar Disorder.

    by Davy Vancampfort, Pascal Sienaert, Sabine Wyckaert, Marc De Hert, Brendon Stubbs, Eugene Kinyanda, Michel Probst

    The prevalence of metabolic syndrome (MetS) in patients with bipolar disorder is 35 to 40%. It is, however, not established yet whether MetS influences participation in physical activity, walking capacity and global functioning. Sixty-five patients (36 ♀) received a full-fasting laboratory screening, performed a walk test including self-report of pre- and post-test pain, and completed the International Physical Activity Questionnaire and the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR16). Patients with (n=24) and without (n=41) MetS did not significantly differ in age, gender, psychotropic medication doses, physical activity, smoking behaviour and global functioning. In contrast, patients with MetS had a significantly (a) longer illness duration, (b) higher BMI, and (c) lower walking capacity. Moreover, patients with MetS scored significantly higher on the QIDS. Patients with MetS reported more pain before and after the walking test and more dyspnea following 6 minutes of walking, indicating the physical health challenges facing people with bipolar disorder and MetS seeking to engage in physical activity. The current data give further credence to the importance of interventions promoting the walking capacity in people with bipolar disorder, in particular in these patients at a high risk for cardiovascular diseases.


  • Type 2 Diabetes Mellitus

    by Davy Vancampfort, Richard I.G. Holt, Brendon Stubbs, Marc De Hert, Katherine Samaras, Alex J. Mitchell


    • 1 September 2015
      • Vol. 27  (3) , 210-24

    What are the factors that influence physical activity participation in individuals with depression? A review of physical activity correlates from 59 studies.

    by Davy Vancampfort, Brendon Stubbs, Pascal Sienaert, Sabine Wyckaert, Marc De Hert, Simon Rosenbaum, Michel Probst

    The present review systematically evaluates correlates of physical activity across the socio-ecological model for people with depression. Two independent reviewers searched Embase, PubMed, and CINAHL from their inception until May 2015, combining the medical subject heading 'depression' or 'depressive' with 'physical activity' or 'exercise'. Data were extracted by the same independent researchers and summarized according to the socio-ecological model. Fifty-nine papers involving 101,539 persons with depression were eligible and enabled us to evaluate 42 correlates. Correlates that were consistently (n ≥ 4) associated with lower physical activity participation in depressed persons were a higher level of depressive symptoms, a higher body mass index, the presence of physical co-morbidity and a lower self-efficacy. The role of social, environmental and policy factors on physical activity participation is unknown and should be addressed in future research. In persons with depression physical activity participation is a complex behavior that is influenced by many different factors. Significant correlates should be confirmed in prospective studies. Interventions to improve modifiable physical and mental health variables in people with depression should be developed and evaluated.


  • Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness

    by Youssef Kouidrat, Ali Amad, Marc De Hert

    Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, are at increased risk of developing metabolic disorders including obesity, diabetes, and dyslipidemia. All of these comorbidities increase the risk of cardiovascular disease and mortality. Different approaches, including diet and lifestyle modifications, behavioral therapy and switching antipsychotic agents, have been proposed to manage these metabolic abnormalities. However, these interventions may be insufficient, impractical or fail to counteract the metabolic dysregulation. Consequently, a variety of pharmacological agents such as antidiabetic drugs, have been studied in an attempt to reverse the weight gain and metabolic abnormalities evident in these patients. Despite a significant effect, many of these treatments are used off-label. This qualitative review focuses on pharmacological agents that could offer significant benefits in the management of cardio-metabolic disorders associated with serious mental illness.


  • Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review

    by M. De Hert, J. Peuskens, T. Sabbe, A. J. Mitchell, B. Stubbs, P. Neven, H. Wildiers, J. Detraux

    Objective: A recent meta‐analysis showed that breast cancer probably is more common in female patients with schizophrenia than in the general population (effect size = 1.25, P < 0.05). Increasing experimental and epidemiological data have alerted researchers to the influence of prolactin (PRL) in mammary carcinogenesis. We therefore investigated the possible relationship between antipsychotic‐induced hyperprolactinemia (HPRL) and breast cancer risk in female patients with schizophrenia.Method: A literature search (1950 until January 2015), using the MEDLINE database, was conducted for English‐language published clinical trials to identify and synthesize data of the current state of knowledge concerning breast cancer risk (factors) in women with schizophrenia and its (their) relationship between HPRL and antipsychotic medication.Results: Although an increasing body of evidence supports the involvement of PRL in breast carcinogenesis, results of human prospective studies are limited, equivocal, and correlative (with risk ratios ranging from 0.70 to 1.9 for premenopausal women and from 0.76 to 2.03 for postmenopausal women). Moreover, these studies equally do not take into account the local production of PRL in breast epithelium, although amplification or overexpression of the local autocrine/paracrine PRL loop may be a more important mechanism in tumorigenesis. Until now, there is also no conclusive evidence that antipsychotic medication can increase the risk of breast malignancy and mortality.Conclusion: Other breast risk factors than PRL, such as nulliparity, obesity, diabetes mellitus, and unhealthy lifestyle behaviours (alcohol dependence, smoking, low physical activity), probably are of greater relevance in individual breast cancer cases within the population of female patients with schizophrenia.


  • Open Access

    Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis

    by Marc De Hert, Anna Eramo, Wally Landsberg, Dusan Kostic, Lan-Feng Tsai, Ross A. Baker

    Purpose: To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), an extended-release injectable suspension of aripiprazole, in obese and nonobese patients. Patients and methods: This post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study (NCT00706654) compared the clinical profile of AOM 400 in obese (body mass index [BMI] ≥30 kg/m2) and nonobese (BMI 10% in any treatment group) were summarized. Results: At baseline of the randomized phase, obesity rates were similar among patients randomized to AOM 400 (n=95/265, 36%), oral aripiprazole (n=95/266, 36%), and AOM 50 mg (n=43/131, 33%). In both obese and nonobese patients, relapse rates through week 38 for patients randomized to AOM 400 (obese, 7.4%; nonobese, 8.8%) were similar to those in patients on oral aripiprazole (obese, 8.4%; nonobese, 7.6%), whereas relapse rates were significantly lower with AOM 400 versus AOM 50 mg (obese, 27.9% [P=0.0012]; nonobese, 19.3% [P=0.0153]). The most common TEAEs with AOM 400 in obese and nonobese patients were insomnia (12.6% and 11.2%), headache (12.6% and 8.2%), injection site pain (11.6% and 5.3%), akathisia (10.5% and 10.6%), upper respiratory tract infection (10.5% and 4.7%), weight increase (10.5% and 8.2%), and weight decrease (6.3% and 11.8%). Within the AOM 400 group, 7.6% of patients who were nonobese at baseline became obese, and 17.9% of obese patients became nonobese during randomized treatment. Conclusion: The clinical profile of AOM 400 was similar in obese and nonobese patients.


  • Health-related physical fitness in patients with bipolar disorder vs. healthy controls: An exploratory study

    by Davy Vancampfort, Pascal Sienaert, Sabine Wyckaert, Marc De Hert, Brendon Stubbs, Andrew Soundy, Jennifer De Smet, Michel Probst


  • Aerobic capacity is associated with global functioning in people with schizophrenia

    by Davy Vancampfort, Hannes Guelinckx, Michel Probst, Philip B. Ward, Simon Rosenbaum, Brendon Stubbs, Marc De Hert

    Background: Although antipsychotic medications help manage clinical symptom severity, most people with schizophrenia continue to function poorly in the community. Objective: To determine whether the Global Assessment of Functioning (GAF) score is associated with aerobic capacity in people with schizophrenia. Method: Thirty-four male (34.1 ± 12.0 years) and 16 female (33.1 ± 8.7 years) persons with schizophrenia performed the Astrand–Rhyming cycle ergometer test in order to estimate the maximal oxygen uptake (VO2max) and were assessed with the GAF, the Psychosis Evaluation tool for Common use by Caregivers and the International Physical Activity Questionnaire. Results: The mean GAF-score was 41.9 ± 9.4, while the mean estimated VO2max was 34.5 ± 8.7mlO2/min/kg. There was a moderate association between the GAF-score and VO2max (r = 0.45, p < 0.001). Positive, negative and cognitive symptoms were negatively (p < 0.05) associated with the GAF-score, physical activity participation positively (p < 0.05). A backward regression analysis demonstrated that VO2max explained 19.1% of the GAF-score variance. Conclusion: In people with schizophrenia, the aerobic capacity is associated with a person’s global functioning. Clinicians should consider incorporating assessment of aerobic capacity into their test battery in order to measure the health consequences of schizophrenia and its treatment.


  • The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis

    by Brendon Stubbs, Alex J. Mitchell, Marc De Hert, Christoph U. Correll, Andy Soundy, Marc Stroobants, Davy Vancampfort


  • Single-subject classification of schizophrenia patients based on a combination of oddball and mismatch evoked potential paradigms

    by Jorne Laton, Jeroen Van Schependom, Jeroen Gielen, Jeroen Decoster, Tim Moons, Jacques De Keyser, Marc De Hert, Guy Nagels